The gastric cancer is the most common malignancy in Korean and the number of them is seemed to be increasing every year. We could made a clinical analysis of 492 cases of the gastric cancer which were operated in the Dept, of Surgery, Kyung Hee
University Hospital from January, 1979 to April, 1986.
@ES The results were as follows:
@EN 1) The age was from 17 years to 78 years old. Peak age incidence was 6th decade(28.9%), the mean age was 52.6 years and the ratio of male to female was 1.8:1.
2) Clinical symptoms, in order of frequency, were epigastric pain(40.2%), weight loss(35.0%), nausea(16.3%) and vomiting(15.4%). On physical examination, epigastric tenderness(39.0%) and palpable abdominal mass(18.3%) were common.
3) Preoperatively, 376 cases(76.4%) were seemed to be resectable and 42 cases(8.5%) were early gastric cancer, But postoperatively, 399 cases(81.1%) were curatively resectable and 90 cases(18.3%) wer early gastric cancer.
4) Distribution of the primary lesion, in order of frequency, wer antrum(71.5%), body(20.5%) and cardia-fudus(8.0%).
5) In TMN staging of the lesion, stage I was 60 cases(12.2%), stage III 64 cases(13.0%), stage III 242 cases(49.2%) and stage IV 126 cases(25.6%).
6) The operative procedure were radical subtotal gastrectomy(69.1%), total gastrectomy(12.0%), palliative resection(4.9%), bypass operation(10.4%) and biopsy only(3.6%).
7) The postoperative complications were developed in 124 cases(15.2%) and common complications were pulmonary complications, wound infection, intraabdominal abscess and enterocutaneous fistula, in order of frequency.
8) The ovrall operative mortality was 2.4%(12/492).
9) The overall 5-year survival rate of all gastric cancer patients was 53.8% and stage I was 94.9%, stage II 81.4%, stage III 52.1% and stage IV 14.9%.
10) IN stage II, 5-year survival rate was 75.9% in none chemotherapy group, 71.4% in MFC group and 91.3% in FAM group(statistically insignificant). In stage III, 5-year survival rate was 37% in none chemotherapy group, 45.9% in MFC group and
60.3%
in
FAM group(statistically significant). In stage IV, statistical significancy was showed between none chemotherapy group and FAM group(8.5%, vs, 23.5%).
|